Denny Ausiello, M.D., is the Jackson Distinguished Professor of Clinical
Medicine, Director, Emeritus of the M.D./Ph.D. Program at Harvard Medical
School, and Director, Center for Assessment Technology and Continuous Health at
MGH. He has made substantial contributions to the knowledge of epithelial
biology in the areas of membrane protein trafficking, ion channel regulation,
and signal transduction. Denny has been advising Verily on its diabetes
initiatives, clinical study designs, and device development since 2015. Denny
received his M.D. from the University of Pennsylvania.
Learn more about Denny Ausiello.
Vikram (Vik) Bajaj
Vik Bajaj, Ph.D., is a co-founder of Verily and currently serves as the
Chair of the Science Board. He is an Associate Professor of Radiology
(consulting) at Stanford University, an affiliate scientist of the University
of California, Berkeley and the Lawrence Berkeley National Laboratory. Vik’s
research interests in industry and as a former academic principal investigator
include structural and systems biology, molecular imaging, nanoscience, and
bioinformatics. Vik received his Ph.D. in Physical Chemistry from MIT.
Learn more about Vik Bajaj.
David Brailer, M.D., Ph.D., is a health care technology investor and
entrepreneur. He was previously the nation’s first National Coordinator for
Health Information Technology from 2004 through 2006, serving under President
George W. Bush. He joined the Verily Science Board in 2016. David received his
Ph.D. in managerial economics from The Wharton School and his M.D. from West
Learn more about David
Karl Deisseroth, Ph.D., is the D.H. Chen Professor, Professor of
Bioengineering, Psychiatry, and Behavioral Sciences at Stanford University. His
research focuses on developing molecular and cellular tools to observe,
perturb, and re-engineer brain circuits. Additionally, he works as a clinician
in the psychiatry department at Stanford. Karl joined the Verily board in 2016.
He received his M.D. and Ph.D. from Stanford University.
Learn more about Karl
Frank is President and CEO of NeuroPace, a medical device company focused on
the treatment of neurological disorders with epilepsy as its first therapeutic
indication. Frank has over 35 years in the medical device industry with the
majority of his career dedicated to the development, clinical evaluation,
regulatory approval and commercialization of products to treat cardiac and
neurological disorders. He joined the Verily Science Board in 2016. Frank
received his M.S. in Management from Rensselaer Polytechnic Institute.
Learn more about Frank
Michael Frumkin has been an Engineering Director at Google since 2002 where he
oversaw large engineering teams as well as critical internal software
infrastructure projects. In 2014 Michael was also an advisor to Khosla
Ventures. Currently he is leading a Google Research team that he founded, whose
aim is to bring Google’s expertise in machine intelligence and perception to
bear on fundamental scientific research. He has been advising on Verily
projects since 2014. Michael graduated with an SM in Computer Science and
Engineering from MIT.
Learn more about Michael
George Loewenstein, Ph.D., is the Herbert A. Simon University Professor of
Economics and Psychology, co-director of the BEDR Policy Lab at Decision
Research at Carnegie Mellon University, and the Director of Behavioral
Economics at the Center for Health Incentives and Behavioral Economics at the
University of Pennsylvania. George is a founder of field of behavioral
economics and neuroeconomics and his current research focuses on various
aspects of information and beliefs. George joined the Verily Science Board in
2016. George received his Ph.D. from Yale University.
Learn more about George Loewenstein.
Nicholas (Nik) Schork
Nicholas (Nik) Schork is Director of Human Biology at the J. Craig Venter
Institute, Distinguished Professor at the Translational Genomics Research
Institute, and Adjunct Professor at the University of California, San Diego.
His interests and expertise are in quantitative human genetics and integrated
approaches to complex biological and medical problems. Nik has been advising
Verily on bioinformatics and genomic research since 2015. He received his Ph.D.
in Epidemiology from the University of Michigan in Ann Arbor.
Learn more about Nik Schork.
Daniel Von Hoff
Daniel Von Hoff, M.D., F.A.C.P., is Distinguished Professor and Physician in
Chief of Translational Research Genomics Institute (TGen). He is also Chief
Scientific Officer for US Oncology Research and for HonorHealth’s Clinical
Research Institute. The focus of his career has been ondeveloping new
anti-cancer agents and more currently on the development of molecularly
targeted therapies for individuals with pancreatic cancer. Dan joined the
Verily Science Board in 2016. He received his M.D. from Columbia University
College of Physicians and Surgeons.
Learn more about Dan Von Hoff.
David Wemmer, Ph.D., is the Joel Hildebrand Distinguished Professor and Chair
of the Department of Chemistry at University of California, Berkeley. David’s
research focuses on biophysical chemistry with the goal of understanding the
interactions which govern the function of biopolymers including proteins, DNA,
and RNA. David has been a science advisor for Verily since 2015. He received
his Ph.D. in Physical Chemistry from University of California, Berkeley.
Learn more about David